ACRS
Aclaris Therapeutics, Inc.
Key Financials
Net Income
$-64923000
↑ 50.8%
Gross Profit
$3.2M
↑ 1925.6%
Revenue
$7.8M
↓ 58.2%
EPS (Diluted)
$-0.53
↑ 69.0%
Total Liabilities
$57.4M
↓ 11.4%
Shareholders' Equity
$103.1M
↓ 33.7%
Cash & Equivalents
$20.0M
↓ 18.8%
Long-term Debt
$10.7M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACRS |
| Company Name | Aclaris Therapeutics, Inc. |
| CIK | 1557746 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 484-324-7933 |